Literature DB >> 16424503

JAMA's policy on industry sponsored studies.

Phil B Fontanarosa, Catherine D DeAngelis.   

Abstract

Entities:  

Mesh:

Year:  2006        PMID: 16424503      PMCID: PMC1336777          DOI: 10.1136/bmj.332.7534.177

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  6 in total

1.  Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.

Authors:  J B Hrachovec; M Mora
Journal:  JAMA       Date:  2001-11-21       Impact factor: 56.272

2.  GlaxoSmithKline to publish clinical trials after US lawsuit.

Authors:  Liza Gibson
Journal:  BMJ       Date:  2004-06-26

3.  Extra scrutiny for industry funded trials.

Authors:  Kenneth J Rothman; Stephen Evans
Journal:  BMJ       Date:  2005-12-10

4.  Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8.

Authors:  Gregory D Curfman; Stephen Morrissey; Jeffrey M Drazen
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

5.  Reporting conflicts of interest, financial aspects of research, and role of sponsors in funded studies.

Authors:  Phil B Fontanarosa; Annette Flanagin; Catherine D DeAngelis
Journal:  JAMA       Date:  2005-07-06       Impact factor: 56.272

6.  Safety issues involving medical devices: implications of recent implantable cardioverter-defibrillator malfunctions.

Authors:  William H Maisel
Journal:  JAMA       Date:  2005-08-24       Impact factor: 56.272

  6 in total
  2 in total

1.  JAMA's policy does not go far enough.

Authors:  Stephen J Senn
Journal:  BMJ       Date:  2006-02-04

2.  More on JAMA's policy on industry sponsored studies.

Authors:  Kenneth J Rothman; Stephen Evans
Journal:  BMJ       Date:  2006-02-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.